MNPR
Monopar Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$117.56
−0.84%Aug 29, 2026, 01:45 UTC
Kim R. Tsuchimoto, a director at Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026, for a total value of $455,566, and exercised options to acquire the same number of shares on the same day.
Source:Aug 12, 2026, 00:00 UTC
Monopar Therapeutics reported a net loss of $5.3 million, or $0.62 per share, for Q2 2026, compared to a net loss of $2.5 million, or $0.35 per share, in Q2 2025.